Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 15000 participants.

Also called NCT05169021

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 15,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05169021
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT05169021. Randomized; no masking; primary purpose prevention. Start 2021-12-31 (anticipated); primary completion 2024-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD
Acronym
FAITH
Condition
Cerebral Small Vessel Diseases
Condition
Stroke
Intervention (Drug)
Amlodipine folic acid 5.8mg+intensive antihypertensive therapy
Intervention (Drug)
Amlodipine folic acid 5.8mg+standard antihypertensive therapy
Intervention (Drug)
Amlodipine+intensive antihypertensive therapy
Intervention (Drug)
Amlodipine+standard antihypertensive therapy
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct05169021
Content hash
b785f1339f2cd377dfb48c9051a92ba35f5e82734f4665fa29c261c35958fad4